JEONJU-CITY
15.10.2021 09:26:04 CEST | Business Wire | Press release
Jeonju , a UNESCO Creative City of Gastronomy, announced that the 2021 Jeonju Bibimbap Festival, the typical gourmet festival of the city, is to be held on every weekend during October 9 - 31, 2021 in the vicinity of Jeonju Hyanggyo in Jeonju Hanok Village and online.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211015005015/en/
Under the title of the World Bibim Week , the bibimbap festival is designed and supervised by Ryu Jae-hyeon, Executive Director, focusing on a food festival to deliver the best taste while promoting sociability that is represented by ‘mixture’. The event is to take place on a small groups reservation basis.
The four week-festival features ‘day’ programs on each weekend under different themes including Bibim Week (Day for Couples), Vitamin Week (Day for Wives), Protein Week (Day for Husbands) and World Week (Day for Families). And other special and standing programs and special exhibitions are also held.
On the first weekend of the Bibim Week (Day for Couples), the event delivers the life-changing meal program ‘Insaeng Matchan', where selected couples are invited to the best restaurants with splendid views to enjoy the full course meals of experienced chefs.
On the second weekend of Vitamin Week (Day for Wives), healthy foods are served that can relieve stress and be beneficial for diets. The healthy and delicious food program 'Geongang Matchan' offers vegetarian meals, poke made of local food ingredients, and a variety of salads for those who want to experience a vegetarian diet or healthy foods. In addition, ‘Buddhist Monk Daean’, an artisan of temple cuisines, introduces gastronomy art, gastronomy & beautiful story meditation and gastronomic vegetarian foods.
The third weekend of the Protein Week (Day for Husbands) prepares a delicious meat foods program ‘Gogi Matchan' to allow husbands to choose gravy-rich meats depending on their own taste.
The fourth weekend of the festival will feature World Week when family members can experience Oriental and Western tastes and culture. The World Week offers a ‘Gastronomy Halloween’ program and campaigns such as ‘Dining with Parents’.
Standing programs this year include taste concert and experiences joined by artisans of Jeonju traditional foods; ‘tastes and concert’ that allows participants to taste foods and enjoy performances; a ‘gastronomy theater’, a wireless theater showing silent films featuring unusual foods; ‘traditional Korean-style house picnic’ that allows visitors to enjoy foods at quiet and still space of Korean-style houses; and special exhibitions using unoccupied stores along the Jeonju Hyanggyo, a Confucian School.
“A pitiful situation is that the limited number of citizens and tourists can enjoy the festival as only those people who are fully vaccinated against COVID-19 are allowed to participate based on advance reservations in small groups,” said an official at tourism industry division, Jeonju City government. “We look forward to seeing citizens and small business runners feel pleasure and comfort with traditional foods and elegant scenes of Hanok Village of Jeonju, the UNESCO Creative City of Gastronomy”.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211015005015/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom